Verona Pharma PLC named Kathleen Rickard its chief medical officer, effective Feb. 1.
In her new role, Rickard will oversee development of Verona Pharma's drug RPL554, a maintenance treatment of chronic obstructive pulmonary disease, cystic fibrosis and possibly asthma.
Rickard has 25 years of experience in clinical research in respiratory medicine, Verona said in a news release. She was previously head of clinical development at Circassia Pharmaceuticals plc. She was also the chief medical officer at Sweden-based medical technology company Aerocrine AB.
London-based Verona Pharma develops and commercializes therapies for respiratory diseases with significant unmet medical needs.